CFTR and cystic fibrosis: Recently, a second-generation corrector, tezacaftor, was developed for the treatment of cystic fibrosis based on the structure of a first-generation corrector, lumacaftor, demonstrating rescue of CFTR folding and function with better pharmacokinetic properties and fewer adverse effects [51].